** Shares of drugmaker Corcept Therapeutics CORT.O rise 19.5% to $43.39 premarket

** Co says its experimental cancer drug, relacorilant, met the main goal in a late-stage trial in patients with platinum-resistant ovarian cancer

** Says the drug with chemotherapy showed a 35% reduction in the risk of death

** CORT previously announced results from another late-stage trial in which the combination treatment helped delay progression of a type of ovarian cancer

** Relacorilant's marketing application is currently under review by the U.S. FDA with a target action date of July 11

** CORT fell 30.9% in 2025

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))